LEADER 03756nam  22006495  450 
001 9910254513203321
005 20200701021724.0
010   $a4-431-55522-6
024 7 $a10.1007/978-4-431-55522-3
035   $a(CKB)3710000000484680
035   $a(EBL)4178995
035   $a(SSID)ssj0001584948
035   $a(PQKBManifestationID)16264560
035   $a(PQKBTitleCode)TC0001584948
035   $a(PQKBWorkID)14864531
035   $a(PQKB)10928811
035   $a(DE-He213)978-4-431-55522-3
035   $a(MiAaPQ)EBC4178995
035   $a(PPN)190515368
035   $a(EXLCZ)993710000000484680
100   $a20151001d2016      u|         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aColitis-Associated Cancer /$fedited by Masato Kusunoki
205   $a1st ed. 2016.
210  1$aTokyo :$cSpringer Japan :$cImprint: Springer,$d2016.
215   $a1 online resource (151 p.)
300   $aDescription based upon print version of record.
311   $a4-431-55521-8 
320   $aIncludes bibliographical references.
327   $aChapter 1 Colitis-Associated Cancer: Overview -- Part I Clinical Features -- Chapter 2 Incidence and Risk Factors -- Chapter 3 Prevention and Prognosis -- Part II. Diagnosis -- Chapter 4 Cancer Surveillance of Patients with Long-Standing Inflammatory Bowel Disease -- Chapter 5 Molecular Alterations in Inflammatory Colonic Carcinogenesis and Markers for Detecting Colitis-Associated Cancer -- Part III. Surgical Treatment -- Chapter 6 Surgical Treatment for Ulcerative Colitis-Associated Cancer or Dysplasia -- Chapter 7 Surgical Treatment for Colorectal Cancer in Crohn?s Disease.
330   $aAs the number of patients with colitis-associated cancer (CAC) is on the increase, the purpose of this book is to review the latest topics concerning management of the disease. In recent years, the diagnostic power of endoscopy and molecular pathology has also grown tremendously, as a result of which they now have a far greater influence on the treatment of CAC. At the moment, appropriate monitoring programs for ulcerative colitis and Crohn?s disease remain uncertain. At the same time, the latest findings on DNA methylation and microRNAs hold the promise of making revolutionary changes in these areas. Moreover, recent drug advances in the treatment of inflammatory bowel diseases have changed surgical indications. On the other hand, the indication of mucosectomy on colorectal cancer in ulcerative colitis and prophylactic abdominoperineal resection for Crohn?s disease remain controversial. This book provides the latest information on the remaining issues of CAC from the point of view of expert surgeons.
606   $aSurgery
606   $aSurgical oncology
606   $aCancer research
606   $aMedical genetics
606   $aSurgery$3https://scigraph.springernature.com/ontologies/product-market-codes/H59001
606   $aSurgical Oncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H59150
606   $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001
606   $aGene Function$3https://scigraph.springernature.com/ontologies/product-market-codes/B12030
615  0$aSurgery.
615  0$aSurgical oncology.
615  0$aCancer research.
615  0$aMedical genetics.
615 14$aSurgery.
615 24$aSurgical Oncology.
615 24$aCancer Research.
615 24$aGene Function.
676   $a616.99434
702   $aKusunoki$b Masato$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910254513203321
996   $aColitis-Associated Cancer$92527148
997   $aUNINA